233 related articles for article (PubMed ID: 37519231)
1. CFTR and PC2, partners in the primary cilia in autosomal dominant polycystic kidney disease.
Yanda MK; Ciobanu C; Guggino WB; Cebotaru L
Am J Physiol Cell Physiol; 2023 Sep; 325(3):C682-C693. PubMed ID: 37519231
[TBL] [Abstract][Full Text] [Related]
2. Zebrafish Model as a Screen to Prevent Cyst Inflation in Autosomal Dominant Polycystic Kidney Disease.
Oliveira I; Jacinto R; Pestana S; Nolasco F; Calado J; Lopes SS; Roxo-Rosa M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445719
[TBL] [Abstract][Full Text] [Related]
3. Ameliorating liver disease in an autosomal recessive polycystic kidney disease mouse model.
Yanda MK; Zeidan A; Cebotaru L
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G404-G414. PubMed ID: 36880660
[TBL] [Abstract][Full Text] [Related]
4. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
Yanda MK; Liu Q; Cebotaru L
J Biol Chem; 2018 Jul; 293(29):11513-11526. PubMed ID: 29875161
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.
Yanda MK; Cha B; Cebotaru CV; Cebotaru L
J Biol Chem; 2019 Nov; 294(45):17090-17104. PubMed ID: 31570523
[TBL] [Abstract][Full Text] [Related]
6. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro.
Davidow CJ; Maser RL; Rome LA; Calvet JP; Grantham JJ
Kidney Int; 1996 Jul; 50(1):208-18. PubMed ID: 8807590
[TBL] [Abstract][Full Text] [Related]
7. VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.
Yanda MK; Cebotaru L
FASEB J; 2021 Nov; 35(11):e21987. PubMed ID: 34662459
[TBL] [Abstract][Full Text] [Related]
8. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
Persu A; Devuyst O; Lannoy N; Materne R; Brosnahan G; Gabow PA; Pirson Y; Verellen-Dumoulin C
J Am Soc Nephrol; 2000 Dec; 11(12):2285-2296. PubMed ID: 11095651
[TBL] [Abstract][Full Text] [Related]
9. Basolateral chloride transporters in autosomal dominant polycystic kidney disease.
Lebeau C; Hanaoka K; Moore-Hoon ML; Guggino WB; Beauwens R; Devuyst O
Pflugers Arch; 2002 Sep; 444(6):722-31. PubMed ID: 12355171
[TBL] [Abstract][Full Text] [Related]
10. Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells.
Jansson K; Venugopal J; Sánchez G; Magenheimer BS; Reif GA; Wallace DP; Calvet JP; Blanco G
J Membr Biol; 2015 Dec; 248(6):1145-57. PubMed ID: 26289599
[TBL] [Abstract][Full Text] [Related]
11. Cilia and polycystic kidney disease.
Ma M
Semin Cell Dev Biol; 2021 Feb; 110():139-148. PubMed ID: 32475690
[TBL] [Abstract][Full Text] [Related]
12. The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.
Talbi K; Cabrita I; Kraus A; Hofmann S; Skoczynski K; Kunzelmann K; Buchholz B; Schreiber R
FASEB J; 2021 Oct; 35(10):e21897. PubMed ID: 34473378
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease.
Yanda MK; Tomar V; Cebotaru L
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1517-1529. PubMed ID: 34329764
[TBL] [Abstract][Full Text] [Related]
14. The heteromeric PC-1/PC-2 polycystin complex is activated by the PC-1 N-terminus.
Ha K; Nobuhara M; Wang Q; Walker RV; Qian F; Schartner C; Cao E; Delling M
Elife; 2020 Nov; 9():. PubMed ID: 33164752
[TBL] [Abstract][Full Text] [Related]
15. Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease.
Shao L; El-Jouni W; Kong F; Ramesh J; Kumar RS; Shen X; Ren J; Devendra S; Dorschel A; Wu M; Barrera I; Tabari A; Hu K; Haque N; Yambayev I; Li S; Kumar A; Behera TR; McDonough G; Furuichi M; Xifaras M; Lu T; Alhayaza RM; Miyabayashi K; Fan Q; Ajay AK; Zhou J
Kidney Int; 2020 Nov; 98(5):1225-1241. PubMed ID: 32610050
[TBL] [Abstract][Full Text] [Related]
16. Ciliary exclusion of Polycystin-2 promotes kidney cystogenesis in an autosomal dominant polycystic kidney disease model.
Walker RV; Keynton JL; Grimes DT; Sreekumar V; Williams DJ; Esapa C; Wu D; Knight MM; Norris DP
Nat Commun; 2019 Sep; 10(1):4072. PubMed ID: 31492868
[TBL] [Abstract][Full Text] [Related]
17. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis.
Xu N; Glockner JF; Rossetti S; Babovich-Vuksanovic D; Harris PC; Torres VE
J Nephrol; 2006; 19(4):529-34. PubMed ID: 17048214
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
[TBL] [Abstract][Full Text] [Related]
19. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.
Li H; Yang W; Mendes F; Amaral MD; Sheppard DN
Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761
[TBL] [Abstract][Full Text] [Related]
20. Tubular STAT3 Limits Renal Inflammation in Autosomal Dominant Polycystic Kidney Disease.
Viau A; Baaziz M; Aka A; Mazloum M; Nguyen C; Kuehn EW; Terzi F; Bienaimé F
J Am Soc Nephrol; 2020 May; 31(5):1035-1049. PubMed ID: 32238474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
